Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
Active, not recruiting · NCT03319901 · Registry updated 2026-06-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hematologic disorder, leukemia, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-06-01 | NCT03319901 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AbbVie | 340 |
| Dana-Farber Cancer Institute | 324 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 133 |
| Intermountain LDS Hospital | Salt Lake City | United States | 1 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| University of Chicago | Chicago | United States | 312 |